Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - vamidothion - unknown - vamidothion organophosphorus active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - vamidothion - unknown - vamidothion organophosphorus active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - vamidothion - insecticide - apple - see label for variety | brussels sprouts | cabbage | cauliflower | chrysanthemum or tanacetum | gladiolus | ornamental | - aphid | bryobia mite | cabbage aphid | carmine mite | european red mite | green peach aphid | potato aphid | thrip | woolly aphid | grey cabbage aphid | red spider mite | spider mite | thrips spp. | two-spotted mite | two-spotted spider mite

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

arysta lifescience benelux sprl - iprodione - suspension concentrate - iprodione carbamate active 500.0 g/l - fungicide - almond | apple - post-harvest dip | apricot | apricot - post-harvest dip | blueberry | boysenberry | celery | cherry | cherry - - alternaria leaf blight or spot blight | black helminthosporium | black leaf blight | blossom blight - sclerotinia fructicola | blossom blight - sclerotinia laxa | blossom blight - sclerotinia spp. | botrytis | brown patch | brown patch - fusarium culmorum | brown rot - monilinia spp. | brown spot on mandarin | curvularia leaf spot | dollar spot | early blight or target blackspot | fusarium patch | grey mould - botrytis cinerea | helminthosporium disease | helminthosporium leaf spot or blight | hypocotyl rot on potato | leaf spot on lawn or turf | lucerne leaf spot | pepper scorch or spot | ripe fruit spot | sclerotinia dropcollar rot of lettuce | sclerotinia rot on peanut | sclerotinia wilt or stem rot | spring dead spot | storage fruit rot | transit rot - suppression | alternaria leaf spot | alternata spot | bipolaris spp. | black scurf | blight | blossom blight | botrytis blight | botrytis rot | botrytis spp | brown spot | bunch rot | bunch rot-grey mould | drechslera dermatiodia | drechslera spp. | exseroh

United States - English - NLM (National Library of Medicine)

cumberland pharmaceuticals inc. - amifostine (unii: m487qf2f4v) (amifostine anhydrous - unii:ila426l95o) - amifostine anhydrous 500 mg in 10 ml - ethyol (amifostine) is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer [see clinical studies (14.1)] . ethyol is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands [see clinical studies (14.2)] . limitation of use do not use ethyol in other settings where chemotherapy can produce a significant survival benefit or cure [see warnings and precautions (5.1)] , or in patients receiving definitive radiotherapy [see warnings and precautions (5.2)] , except in the context of a clinical study. ethyol is contraindicated in patients with known hypersensitivity to aminothiol compounds. when ethyol is used in combination with cisplatin, refer to the cisplatin full prescribing information for pregnancy information. based on findings in animals, ethyol ca

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - amifostine, quantity: 500 mg - injection, powder for - excipient ingredients: - to decrease the incidence of neutropenia related fever and infection induced by dna-binding chemotherapeutic agents (classical alkylating agents such as cyclophosphamide and non-classical alkylating agents such as mitomycin-c and platinum-containing drugs); decrease in the incidence of acute and cumulative nephrotoxicity associated with platinum-based therapy; and the provision of better adherence to these types of chemotherapy regimens. indications as at 31 march 2000: ethyol is indicated to decrease the incidence of neutropenia-related fever and infection induced by dna-binding chemotherapeutic agents (classical alkylating agents such as cyclophosphamide and non-classical alkylating agents such as mitomycin-c and platinum containing drugs); decrease the incidence of acute and cumulative nephrotoxicity associated with platinum-based therapy; and to provide better adherence to these types of chemotherapy regimens. ethyol is also indicated to protect against acute and late xerostomia associated with standard

United States - English - NLM (National Library of Medicine)

clinigen limited - amifostine (unii: m487qf2f4v) (amifostine anhydrous - unii:ila426l95o) - ethyol (amifostine) is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer [see clinical studies (14.1)] . ethyol is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands [see clinical studies (14.2)] . limitation of use do not use ethyol in other settings where chemotherapy can produce a significant survival benefit or cure [see warnings and precautions (5.1)] , or in patients receiving definitive radiotherapy [see warnings and precautions (5.2)] , except in the context of a clinical study. ethyol is contraindicated in patients with known hypersensitivity to aminothiol compounds. when ethyol is used in combination with cisplatin, refer to the cisplatin full prescribing information for pregnancy information. based on findings in animals, ethyol can cause fetal harm when administered to a pregnant woman. there are no available data on ethyol use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, intravenous administration of ethyol to pregnant rabbits during organogenesis was embryotoxic at doses approximately sixty percent of the recommended dose in humans based on body surface area (see data) . advise pregnant women and females of reproductive potential of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown. however, the estimated background risk of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies in the u.s. general population. ethyol has been shown to be embryotoxic in rabbits at intravenous doses of 50 mg/kg, approximately sixty percent of the recommended dose in humans on a body surface area basis. when ethyol is used in combination with cisplatin, refer to the cisplatin full prescribing information for lactation information. there are no data on the presence of amifostine or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment with ethyol. when ethyol is used in combination with cisplatin, refer to the cisplatin full prescribing information for contraception and infertility information. verify pregnancy status in females of reproductive potential prior to initiating ethyol. males based on findings from animal studies, ethyol may impair fertility in males of reproductive potential [see nonclinical toxicology (13.1)]. the safety and effectiveness in pediatric patients have not been established. the clinical studies did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy in elderly patients.

Singapore - English - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - coal tar solution; salicylic acid - shampoo - 4.25% - coal tar solution 4.25%; salicylic acid 2%

Australia - English - Department of Health (Therapeutic Goods Administration)

siggie pty ltd - 61087 - clinical management support web-based application software - siggie software is a clinical management support software application that may be accessed by digital devices, both online (web based) and offline (application software). the software assists patients and their clinicians to efficiently complete clinical mental health diagnostic assessments by simplifying the collection, analysis and interpretation of mental health data the software: 1. assists patients to provide relevant data by responding to specific questions 2. assists clinicians to review and refine this data by responding to specific questions 3. assists patients and clinicians to work together to analyse, interpret and refine this data in order to generate: - a provisional diagnosis (if applicable) which requires validation by the clinician (and whenever possible) by the patient - a provisional evidence-based treatment plan informed by the provisional diagnosis and relevant clinical practice guidelines, which also requires validation by the clinician (and whenever possible) by the patient 4. assists the patient and clinician to work together to monitor the patient's response to treatment utilising diagnostic tools and outcome measures siggie is designed to compliment and enhance (not replace) the patient / clinician relationship by assisting them to efficiently navigate the diagnostic assessment and management process. all data inputs and outputs require validation by the patient and the clinician, and the clinician retains clinical autonomy with the ability to override and/or modify any clinical recommendations. siggie digitalises the content and logic contained in: - the psychiatric clinical diagnostic assessment - the dsm-5 and icd-10/11 mental health diagnostic classification systems - up to date evidence-based clinical practice guidelines for the treatment of mental disorders - relevant mental health literature this information is in the public domain and can be readily accessed by patients and clinicians, both online and in paper form eg. through public libraries

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

roche (malaysia) sdn. bhd. - trastuzumab; pertuzumab -